| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:14636701 | IVR | 5 mg/kg | 5 mg/kg | Affects cytokine signaling | Immunological endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:15646816 | IVR | 0.1 mg/kg | 0.1 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| PMID:21318220 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000002 M | 0.0000002 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000005 M | 0.000005 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:23496416 | IVR | 12 mg | 12 mg | Decreased prostate weights | Reproductive endocrine-mediated perturbations |
| IVR | 12 mg | 12 mg | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg | 12 mg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg | 12 mg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:35163327 | IVR | 0.01 - 0.1 mg/kg/day | 0.01 - 0.1 mg/kg/day | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 - 0.1 mg/kg/day | 0.01 - 0.1 mg/kg/day | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.